Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + anlotinib + eribulin as first-line therapy for advanced unresectable soft tissue sarcoma
ChiCTR2300072293Phase 2Recruiting
- Sponsor
- Beijing Chaoyang Sanhuan Cancer Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab, anlotinib and eribulin in soft tissue sarcoma (STS), sponsored by Beijing Chaoyang Sanhuan Cancer Hospital. Primary endpoint: Objective Response Rate. Started Jun 2023; status: recruiting.
02
Drugs
zimberelimabanlotiniberibulin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2300072293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072293.